Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Hepatology. 2011 Aug 11;54(4):1135–1148. doi: 10.1002/hep.24489

Figure 2. Induction of cross-reactive neutralizing antibodies following homologous HCV re-challenge.

Figure 2

CH10273 was challenged with heterologous H77 at week 0. CH10274 was re-challenged three times with homologous JFH1-HCVcc (genotype 2a) at week 0, 6, and 12 and heterologous challenge with H77 (genotype 1a) at week 22. Serum samples of both chimpanzees were tested at the indicated weeks for the presence of neutralizing antibodies. For the determination of neutralizing antibodies, the percent of pseudoparticle infection bearing the JFH1 (genotype 2a) or the H77 (genotype 1a) envelope proteins was measured and compared to pseudoparticle infection in the presence of human control sera (=100%). Experiments were done in triplicates, and the standard deviation is indicated. The neutralizing activity was defined as ≥ 50% reduction in HCVpp entry indicated by a dashed line. The arrows and circle indicate the time points of the first homologous and heterologous HCV re-challenges.